Related Experiment Video
Updated: Jun 23, 2025
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
SLC4A4 is a novel driver of enzalutamide resistance in prostate cancer
Hao-Jie Chen1, Ming-Ming Yu2, Jia-Cheng Huang3
1Department of Urology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200062, China; Department of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200092, China.
Abstract:
The androgen receptor signaling inhibitor (ARSI) enzalutamide (Enz) has shown critical efficacy in the treatment of advanced prostate cancer (PCa). However, the development of drug resistance is a significant factor contributing to mortality in PCa patients. We aimed to explore the key mechanisms of Enz-resistance. Through analysis of GEO databases, we identified SLC4A4 as a novel driver in Enz resistance. Long-term Enz treatment leads to the up-regulation of SLC4A4, which in turn mediates P53 lactylation via the NF-κB/STAT3/SLC4A4 axis, ultimately leading to the development of Enz resistance and progression of PCa. SLC4A4 knockdown overcomes Enz resistance both in vitro and in vivo. Hence, our results suggest that targeting SLC4A4 could be a promising therapeutic strategy for Enz resistance. STATEMENT OF SIGNIFICANCE: SLC4A4 is a novel driver of enzalutamide resistance.
Insights
Enzalutamide resistance in prostate cancer is driven by SLC4A4, which mediates P53 lactylation. Targeting SLC4A4 offers a promising strategy to overcome treatment resistance and improve outcomes for advanced prostate cancer patients.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Advanced prostate cancer (PCa) treatment often involves androgen receptor signaling inhibitors (ARSIs) like enzalutamide (Enz).
- Drug resistance to Enz is a major cause of mortality in PCa patients.
- Understanding the mechanisms of Enz resistance is crucial for developing effective therapies.
Purpose of the Study:
- To identify key molecular mechanisms driving enzalutamide resistance in prostate cancer.
- To investigate the role of SLC4A4 in the development of Enz resistance.
Main Methods:
- Analysis of Gene Expression Omnibus (GEO) databases to identify potential resistance drivers.
- Investigating the NF-κB/STAT3/SLC4A4 axis and its role in P53 lactylation.
- In vitro and in vivo experiments involving SLC4A4 knockdown.
Main Results:
- SLC4A4 was identified as a novel driver of Enz resistance in PCa.
- Long-term Enz treatment up-regulates SLC4A4 expression.
- SLC4A4 mediates P53 lactylation through the NF-κB/STAT3/SLC4A4 axis, promoting Enz resistance and PCa progression.
- Knockdown of SLC4A4 effectively overcomes Enz resistance in preclinical models.
Conclusions:
- SLC4A4 is a critical mediator of enzalutamide resistance in prostate cancer.
- Targeting SLC4A4 presents a potential therapeutic strategy to overcome Enz resistance.
- Further research into the SLC4A4 pathway could lead to novel treatment approaches for advanced PCa.
Related Concept Videos
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...